Robert Cavorsi's most recent trade in Organogenesis Holdings Inc - Ordinary Shares - Class A was a trade of 700 Class A Common Stock done at an average price of $3.2 . Disclosure was reported to the exchange on March 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.21 per share. | 01 Mar 2026 | 700 | 275,524 (0%) | 0% | 3.2 | 2,247 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 93,750 | 265,257 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 53,452 | 53,452 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 16,454 | 281,711 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2026 | 16,290 | 281,547 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.84 per share. | 18 Feb 2026 | 5,487 | 276,224 (0%) | 0% | 3.8 | 21,070 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.84 per share. | 18 Feb 2026 | 5,432 | 276,115 (0%) | 0% | 3.8 | 20,859 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 15 Feb 2026 | 6,667 | 182,498 (0%) | 0% | 3.7 | 24,868 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 15 Feb 2026 | 5,549 | 176,949 (0%) | 0% | 3.7 | 20,698 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.73 per share. | 15 Feb 2026 | 5,442 | 171,507 (0%) | 0% | 3.7 | 20,299 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.46 per share. | 16 Jul 2025 | 360 | 189,165 (0%) | 0% | 4.5 | 1,607 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.16 per share. | 09 Mar 2025 | 210 | 189,586 (0%) | 0% | 5.2 | 1,084 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.16 per share. | 09 Mar 2025 | 61 | 189,525 (0%) | 0% | 5.2 | 315 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.21 per share. | 01 Mar 2025 | 667 | 189,796 (0%) | 0% | 6.2 | 4,142 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 63,830 | 63,830 | - | - | Stock Option (Right to Buy) | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 61,705 | 190,463 (0%) | 0% | 0 | Class A Common Stock | |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 6,008 | 128,758 (0%) | 0% | 3.7 | 22,230 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 15 Feb 2025 | 5,000 | 134,766 (0%) | 0% | 3.7 | 18,500 | Class A Common Stock |
| Organogenesis Holdings Inc (Class A) | Robert Cavorsi | Vice President, Strategy | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.09 per share. | 16 Jul 2024 | 317 | 139,766 (0%) | 0% | 3.1 | 980 | Class A Common Stock |